A Study of Molecular Anatomic Imaging Analysis of Tau, the Primary Pathological Protein in Progressive Supranuclear Palsy

Overview

Información sobre este estudio

The purpose of this study is to learn more about the distribution of the pathological protein tau in the living brains of patients with Progressive Supranuclear Palsy (PSP).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • All subjects will be over age 35.
  • Must present with gradual progression of PSP-related symptoms.
  • Must have an informant to provide independent evaluation of functioning.  
  • All subjects must meet the 2017 Movement Disorder Society clinical criteria for PSP, including any of the clinical presentations of PSP such as PSP with Richardson’s syndrome, PSP with progressive gait freezing, PSP with predominant parkinsonism,  PSP with predominant frontal presentation, PSP with ocular motor dysfunction, PSP with predominant speech/language disorder and PSP with predominant CBS.
  • PSP subjects must be able to ambulate (either aided or unaided) in order to undergo the optional gait examination.

Exclusion Criteria:

  • Subjects who do not have the symptoms necessary to fulfill inclusion criteria for PSP.
  • Subjects with concurrent illnesses that could account for their symptoms such as traumatic brain injury, encephalitis, strokes or developmental syndromes.
  • Women that are pregnant or post-partum and breast-feeding.
  • All women who can become pregnant must have a pregnancy test before the PET scan.
  • Subjects will be excluded if they have any of the following genetic conditions which can increase the chance of cancer:
    • Cowden disease;
    • Lynch syndrome;
    • Hypogammaglobulinemia;
    • Wiskott-Aldrich syndrome;
    • Down’s syndrome.
  • Subjects if MRI is contraindicated (metal in head, cardiac pacemaker, etc.).
  • Subjects with severe claustrophobia.
  • Subjects with conditions that may confound brain imaging studies (e.g., structural abnormalities including subdural hematoma, intracranial neoplasm or large cortical infarcts).
  • Subjects who are medically unstable or are on medications that might affect brain structure or metabolism (e.g., chemotherapy).

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Keith Josephs, M.D.

Abierto para la inscripción

Contact information:

Sarah Boland CCRP

(507)284-3863

Boland.Sarah@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20167661

Mayo Clinic Footer